An Open Label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Patients With Various Advanced or Metastatic Non-hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2015
At a glance
- Drugs BI 853520 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 01 Dec 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.